Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tucidinostat + nab-paclitaxel
- Development stage
- Phase 2
- Lead developer
- Akeso
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Intravenous
01
Overview
Tucidinostat + nab-paclitaxel is a combination therapy being evaluated for the treatment of advanced hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Tucidinostat (also known as chidamide) is an orally bioavailable, subtype-selective histone deacetylase (HDAC) inhibitor that targets HDAC1, 2, 3, and 10. It acts as an epigenetic modulator, reversing resistance to endocrine therapy and enhancing immune response. Nab-paclitaxel is an albumin-bound nanoparticle formulation of the microtubule inhibitor paclitaxel, designed to improve solubility and delivery to tumor tissues. This specific combination is being investigated in a Phase II clinical trial sponsored by Hunan Cancer Hospital to assess safety and efficacy in postmenopausal women whose disease has progressed.
- Other names
- chidamidenanoparticle albumin-bound paclitaxelnab-paclitaxel
02
Targets
HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC11 (Histone Deacetylase 11)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)HDAC8 (Histone Deacetylase 8)SPARC (Secreted protein acidic and rich in cysteine)gp60 (GP60 Receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on tucidinostat + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tucidinostat + nab-paclitaxel.